Investment Thesis Cara Therapeutics ( CARA ) recently reported top-line results of its Phase III KALM-1 U.S. clinical study of KORSUVA Injection in Hemodialysis Patients with moderate-to-severe Pruritus. Following the positive phase III KALM-1 clinical trial results, the stock price surged…